435 related articles for article (PubMed ID: 21839812)
1. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
[TBL] [Abstract][Full Text] [Related]
2. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
Pisanu A; Lecca D; Mulas G; Wardas J; Simbula G; Spiga S; Carta AR
Neurobiol Dis; 2014 Nov; 71():280-91. PubMed ID: 25134730
[TBL] [Abstract][Full Text] [Related]
3. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Caboni P; Garau A; Carboni E; Carta AR
Eur J Neurosci; 2009 Mar; 29(5):954-63. PubMed ID: 19245367
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
5. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Garau A; Carboni E; Carta AR
Neurotox Res; 2009 Aug; 16(2):127-39. PubMed ID: 19526289
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.
Frau L; Borsini F; Wardas J; Khairnar AS; Schintu N; Morelli M
Synapse; 2011 Mar; 65(3):181-8. PubMed ID: 20665698
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
Luo Y; Yin W; Signore AP; Zhang F; Hong Z; Wang S; Graham SH; Chen J
J Neurochem; 2006 Apr; 97(2):435-48. PubMed ID: 16539667
[TBL] [Abstract][Full Text] [Related]
8. Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression.
Sadeghian M; Marinova-Mutafchieva L; Broom L; Davis JB; Virley D; Medhurst AD; Dexter DT
J Neuroimmunol; 2012 May; 246(1-2):69-77. PubMed ID: 22498097
[TBL] [Abstract][Full Text] [Related]
9. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-γ-independent mechanisms.
Thal SC; Heinemann M; Luh C; Pieter D; Werner C; Engelhard K
J Neurotrauma; 2011 Jun; 28(6):983-93. PubMed ID: 21501066
[TBL] [Abstract][Full Text] [Related]
11. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
[TBL] [Abstract][Full Text] [Related]
12. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor.
García C; Gómez-Cañas M; Burgaz S; Palomares B; Gómez-Gálvez Y; Palomo-Garo C; Campo S; Ferrer-Hernández J; Pavicic C; Navarrete C; Luz Bellido M; García-Arencibia M; Ruth Pazos M; Muñoz E; Fernández-Ruiz J
J Neuroinflammation; 2018 Jan; 15(1):19. PubMed ID: 29338785
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
14. Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson's disease models.
Lecca D; Janda E; Mulas G; Diana A; Martino C; Angius F; Spolitu S; Casu MA; Simbula G; Boi L; Batetta B; Spiga S; Carta AR
Br J Pharmacol; 2018 Aug; 175(16):3298-3314. PubMed ID: 29570770
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice.
Lecca D; Nevin DK; Mulas G; Casu MA; Diana A; Rossi D; Sacchetti G; Fayne D; Carta AR
Neuroscience; 2015 Aug; 302():23-35. PubMed ID: 25907448
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Goldberg NR; Haack AK; Lim NS; Janson OK; Meshul CK
Neuroscience; 2011 Apr; 180():256-71. PubMed ID: 21335067
[TBL] [Abstract][Full Text] [Related]
17. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha.
Sriram K; Matheson JM; Benkovic SA; Miller DB; Luster MI; O'Callaghan JP
FASEB J; 2006 Apr; 20(6):670-82. PubMed ID: 16581975
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
19. Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
Laloux C; Petrault M; Lecointe C; Devos D; Bordet R
Pharmacol Res; 2012 May; 65(5):514-22. PubMed ID: 22391246
[TBL] [Abstract][Full Text] [Related]
20. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.
Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO
Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
